Author: Ken Dropiewski

Cardisio Demonstrates Unprecedented Accuracy in New Non-Invasive Coronary Artery Disease Detection

Peer-Reviewed Study Published in the ‘Journal of Electrocardiology’ Confirms Cardisio’s Non-Invasive, Low-Cost Test as a Highly Accurate CAD Detection Tool FRANKFURT, Germany, Jan. 13, 2020 /PRNewswire/ — The Journal of Electrocardiology has published a study showing unparalleled accuracy in non-invasive coronary artery disease (CAD) detection using Cardisio’s new low-cost method which involves no radiation exposure. […]

PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq Listing Rule 5550(a)(2) after 10 consecutive days with a […]

Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year

SAN FRANCISCO–(BUSINESS WIRE)–Jan. 13, 2020– Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported preliminary, unaudited, third quarter fiscal 2020 revenue of approximately $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Abiomed had a strong start to the quarter across […]

PQ Bypass Announces 100th Patient in Clinical Study to Evaluate Percutaneous Fem-Pop Bypass for Extremely Long Blockages in Leg Arteries

DETOUR Procedure Designed to Move Treatment from Inpatient to Outpatient Setting MILPITAS, Calif.–(BUSINESS WIRE)–Silicon Valley-based medical device company PQ Bypass announced today the 100th patient in the DETOUR2 Clinical Trial, which evaluates the safety and effectiveness of the minimally invasive DETOUR procedure for percutaneous femoropopliteal bypass. The case was performed […]

Cardiologs Raises $15 Million in Series A Funding Led by Alven

Funding will accelerate adoption of the company’s breakthrough AI-based heart disease diagnostic solution by supporting physicians with unprecedented EKG data analysis and reporting capabilities PARIS and BOSTON, Jan. 10, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced that it has secured  $15 million in Series A funding, bringing the total capital […]

Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation

Positive pre-clinical and clinical proof-of-concept data of Sequana Medical’s innovative DSR therapy published in top tier peer-reviewed cardiovascular journal Data demonstrates potential for treatment of volume overload due to heart failure Ghent, BELGIUM – 10 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid […]

Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy). “The […]

Matinas BioPharma Announces Proposed Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) — (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Matinas BioPharma intends to grant the […]

Cardiva Medical Appoints Jeri Hilleman to the Company’s Board of Directors

SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl (“Jeri”) Hilleman to the company’s Board of Directors. “We are thrilled to welcome Jeri to our team and look forward to leveraging her deep expertise with high-growth […]

FDA Grants Breakthrough Device Designation to Reflow Medical’s Temporary Spur Stent System

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical announces that the Temporary Spur Stent System, a novel retrievable stent technology intended for the treatment of below-the-knee (BTK) peripheral artery disease, has been designated for the Breakthrough Devices Program by the U.S. Food and Drug Administration (FDA). The Breakthrough Devices Program is designed to […]